We further assessed the potential for PSMD3 to act as an oncogene in FLT3+ AML both in vitro and in vivo, and whether other 19S proteasome subunits could serve as novel prognostic biomarkers. This evidence concerns the gene PSMD3 and acute myeloid leukemia.